Jason Bednar

Q: What is Jason Bednar's success rate?

Jason Bednar currently has a success rate of 95.62552088063391.

Q: What is the average return of Jason Bednar's calls?

Their stock ratings have generated an average return of 19.687876011179103.

Piper Sandler | Healthcare

Jason Bednar is an analyst from Piper Sandler specializing in the Healthcare sector. Ranked #835 out of 4565 analysts, they have issued 32 stock ratings with a success rate of 95.63% and an average return of 19.69%.

Jason Bednar has a well-established track record, with 32 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 95.63% and an average return of 19.69%, underscoring their expertise and ability to identify winning opportunities for investors.

#835

Out of 4565

Total Ratings

+95.63%

Success Rate

+19.69%

Average Return

Recent Ratings Analysis

DRTS

Hold

Mar 04, 2026

Target

$5.00

Current

$7.07

Performance

Jason Bednar rated DRTS as Neutral on Mar 04, 2026, setting a price target of 5. The Hold stance appears justified, as shares hovered around 7.07 with a % move.

ICUI

Buy

Feb 20, 2026

Target

$178.00

Current

$142.66

Performance

-9.15%

On Feb 20, 2026, ICUI was given a Overweight rating by Jason Bednar, with a target price of 178. Despite the Buy call, shares fell from 142.66 to 142.66, challenging the optimistic stance.

MMSI

Buy

Feb 18, 2026

Target

$113.00

Current

$74.85

Performance

-9.80%

MMSI received a Overweight rating from Jason Bednar on Feb 18, 2026, aiming for 113. The rating hasn’t played out as hoped, with the stock trading 9.80% below expectations.

BDX

Hold

Feb 10, 2026

Target

$205.00

Current

$174.21

Performance

1.47%

On Feb 10, 2026, Jason Bednar published a Neutral outlook on BDX, with a target of 205. Sideways action left the Hold view intact, with no major move since 174.21.

NVST

Hold

Feb 06, 2026

Target

$25.00

Current

$28.67

Performance

-1.48%

Jason Bednar on Feb 06, 2026 assigned NVST a Neutral rating, with a price target of 25. The Hold stance reflected consolidation, as shares held near 28.67.

ALGN

Buy

Feb 05, 2026

Target

$220.00

Current

$182.64

Performance

4.00%

On Feb 05, 2026, Jason Bednar reaffirmed ALGN with a Overweight rating, targeting 220. Market indecision has kept the 220 target in a holding pattern.

GEHC

Buy

Jan 30, 2026

Target

$94.00

Current

$78.13

Performance

-1.06%

GEHC was rated Overweight by Jason Bednar on Jan 30, 2026, with a price objective of 94. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

MDLN

Buy

Jan 12, 2026

Target

$50.00

Current

$44.39

Performance

3.91%

On Jan 12, 2026, Jason Bednar initiated coverage on MDLN with a Overweight rating and target of 50. Neutral price movement of 3.91% leaves room for interpretation.

SHC

Buy

Jan 09, 2026

Target

$24.00

Current

$15.70

Performance

-18.23%

Jason Bednar issued a Overweight recommendation for SHC on Jan 09, 2026, price target set at 24. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

COO

Buy

Dec 05, 2025

Target

$94.00

Current

$83.37

Performance

2.42%

On Dec 05, 2025, COO was evaluated by Jason Bednar, who gave a Overweight rating and target of 94. So far, the Buy call awaits clearer momentum, with shares flat at 83.37.

SOLV

Buy

Nov 07, 2025

Target

$98.00

Current

$70.81

Performance

-0.99%

Jason Bednar rated SOLV as Overweight on Nov 07, 2025, setting a price target of 98. Shares have remained stable near 70.81, leaving the 98 target still in play.

MASI

Buy

Aug 06, 2025

Target

$210.00

Current

$175.36

Performance

21.23%

On Aug 06, 2025, MASI was given a Overweight rating by Jason Bednar, with a target price of 210. The stock rallied 21.23% after the rating, narrowing the gap to the target of 210 and validating the bullish stance.

LUNG

Hold

Jul 31, 2025

Target

$2.50

Current

$1.53

Performance

-16.85%

LUNG received a Neutral rating from Jason Bednar on Jul 31, 2025, aiming for 2.5. The Hold stance proved prudent, with the market softening by 16.85%.

NVCR

Buy

Jun 27, 2025

Target

$34.00

Current

$13.30

Performance

-26.11%

On Jun 27, 2025, Jason Bednar published a Overweight outlook on NVCR, with a target of 34. Market action contradicted the Buy thesis, as shares slipped to 13.3.

EDAP

Buy

Mar 28, 2025

Target

$4.50

Current

$3.99

Performance

88.21%

Jason Bednar on Mar 28, 2025 assigned EDAP a Overweight rating, with a price target of 4.5. The Buy call aligned well with market performance, producing a gain of 88.21%.

KRMD

Hold

Feb 14, 2025

Target

$4.50

Current

$4.77

Performance

9.15%

On Feb 14, 2025, Jason Bednar reaffirmed KRMD with a Neutral rating, targeting 4.5. Market strength beyond 4.77 went further than the conservative outlook suggested.

STE

Buy

Feb 03, 2025

Target

$265.00

Current

$243.35

Performance

11.45%

STE was rated Overweight by Jason Bednar on Feb 03, 2025, with a price objective of 265. A bullish response from the market helped close the gap of 21.65 to the target.

PDCO

Hold

Dec 06, 2024

Target

$24.00

Current

$31.33

Performance

36.69%

On Dec 06, 2024, Jason Bednar initiated coverage on PDCO with a Neutral rating and target of 24. The Hold stance underestimated the stock’s strength as it gained 36.69%.

XAIR

Buy

Jun 25, 2024

Target

$3.50

Current

$0.85

Performance

-93.45%

Jason Bednar issued a Overweight recommendation for XAIR on Jun 25, 2024, price target set at 3.5. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

HSIC

Buy

Jun 21, 2024

Target

$86.00

Current

$80.21

Performance

19.25%

On Jun 21, 2024, HSIC was evaluated by Jason Bednar, who gave a Overweight rating and target of 86. This case illustrates how a timely bullish rating can translate into tangible gains of 19.25%.

XRAY

Hold

May 03, 2024

Target

$32.00

Current

$13.30

Performance

-52.99%

Jason Bednar rated XRAY as Neutral on May 03, 2024, setting a price target of 32. The cautious Hold call aligned with subsequent weakness, as shares slipped 52.99%.

Frequency Asked Questions

Who is Jason Bednar?

Jason Bednar is an analyst from Piper Sandler specializing in the Healthcare sector.

What is Jason Bednar's success rate?

Jason Bednar currently has a success rate of +95.63%.

How many ratings has Jason Bednar issued?

Jason Bednar has issued 32 stock ratings so far.

What is the average return of Jason Bednar's calls?

Their stock ratings have generated an average return of +19.69%.

What is Jason Bednar's ranking?

Jason Bednar is ranked #835 out of 4565 analysts.

What types of ratings does Jason Bednar give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Jason Bednar?

You can follow Jason Bednar by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Jason Bednar?

Their latest rating was a Hold on DRTS issued on 2026-03-04.